Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as
adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric
and esophagogastric junction adenocarcinoma and high risk of recurrence (defined by ypN1-3
and/or R1 status) following neoadjuvant chemotherapy and resection.
Other study objectives:
- To investigate the safety and effect of adjuvant immunotherapy on long term oncologic
outcomes and quality of life of patients in the study
- To correlate nutritional status assessment on outcomes and quality of life of patients
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC